thrombotic

Efegatran sulfate (LY294468 sulfate) is a potent thrombin inhibitor used in the treatment of thrombotic disorders.

α-Linolenic acid (Alpha-Linolenic Acid) is an essential fatty acid belonging to the omega-3 fatty acids group. It is highly concentrated in certain plant oils and has been reported to inhibit the synthesis of prostaglandin resulting in reduced inflammation and prevention of certain chronic diseases.

Atorvastatin is an orally active HMG-CoA reductase inhibitor that has the ability to effectively lower blood lipids by activating liver cytochrome p450 to accelerate metabolism. Atorvastatin inhibited proliferation and invasion of human SV-SMC cells with IC50 values of 0.39 μM and 2.39 μM, respectively. Atorvastatin combined with clopidogrel may lead to increased thrombotic events in patients.

Poloxamer 188, a nonionic linear copolymer possessing surfactant properties, demonstrates anti-thrombotic, anti-inflammatory, and cytoprotective activities across different tissue injury models.

Cycloolivil (Isoolivil) is a natural polyphenolic compound with a significant radical scavenging activity present in olive trees. Cycloolivil has antioxidant activity, it may prevent thrombotic complications associated to platelet hyperaggregability and be the base

Mumefural, a bioactive compound found in the processed fruit of Prunus mume Sieb., inhibits platelet aggregation, exhibits anti-thrombotic properties, and ameliorates cognitive impairment [1] [2].

Batroxobin (DF-521), a venom derived from the Bothrops atrox moojeni snake, facilitates thrombolysis, inhibits thrombus reformation, and offers neuroprotection. It holds research potential for treating cerebral venous thrombotic diseases [1].

Caplacizumab (ALX-0681), a humanized anti-von Willebrand factor (vWF) nanobody, serves to impede vWF-mediated platelet adhesion, thereby averting additional microthrombi formation. This compound is utilized in the study of thrombotic thrombocytopenic purpura (TTP) [1].

Letaxaban (TAK-442) is a small molecule Xa factor inhibitor that can be used to study polar coronary syndromes and thrombotic blockages.

Inogatran is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of venous and arterial thrombotic diseases.

F-050 is a biochemical that has been shown to inhibit platelet aggregation induced by CaCl2, arachidonic acid, collagen, adenosine diphosphate (ADP) and thrombin in guinea pigs, rabbits and rats in vitro. F-050 may be useful in the treatment of thrombotic diseases.

(1R,3S)-THCCA-Asn (4j) is a selective inhibitor of thrombin (IC50: 0.07-0.14 μM) with anti-thrombotic effects.

Protease-Activated Receptor-1 antagonist 1 (Compound 13) is a protease-activated receptor 1 (PAR-1) antagonist with an IC50 of 3 nM obtained by the FLIPR technique. antagonist 1 can be used to study thrombotic cardiovascular, myocardial infarction and peripheral arterial disease.

FXIa-IN-8 is a potent and selective inhibitor of FXIa (IC50: 14.2 nM). FXIa-IN-8 exhibits anti-thrombotic effects and does not increase the risk of bleeding or significant toxicity sup>[1].

6-Hydroxykaempferol 3-O-beta-D-glucoside has anti-thrombotic,and antioxidative activities.

Danshenxinkun A, Danshenxinkun B and Neocryptotanshinone may intervene thrombotic diseases by adjusting the targets mainly involved in pathways of endocrine system, signal transduction, signaling molecules and interaction, cell motility, environmental ada

Protodeltonin may have anti-thrombotic activity by both improving the anticoagulation activity and inhibiting platelet aggregation action. Protodeltonin can inhibit the proliferation of a panel of established human and murine cancer cell lines in vitro.

O-Demethyl apixaban sulfate is a metabolite of Apixaban, a potent and highly selective factor Xa inhibitor. Apixaban is currently under development for treatment of arterial and venous thrombotic diseases.

Fondaparinux Free Base is a synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery. Fondaparinux is a clinically approved anticoagulant pentasaccharide for the treatment of thrombotic diseases, displays better efficacy and biosafety than other heparin-based anticoagulant drugs.

Liriope muscari baily saponins C has an anti-thrombotic activity due to down-regulation of the increased mRNA expression levels of TF and IL-6.

Egaptivon pegol (ARC1779) is an aptamer that inhibits the interaction of von Willebrand Factor (VWF) with platelet GPIb receptors, exhibiting anti-thrombotic efficacy.

SC99 is a selective inhibitor of JAK2-STAT3 activation. SC99 downregulates the expression of STAT3-modulated genes.SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities